13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Brain Tumors and Neuro-Oncology
Brain tumors and neuro-oncology are integral to addressing the complexities of primary and secondary brain cancers. This specialized field encompasses a range of treatment options, from surgery and radiation therapy to cutting-edge drug therapies and clinical trials exploring new drug combinations. Researchers are focused on overcoming the challenges posed by the blood-brain barrier to deliver effective treatments. With the advent of immunotherapy, CAR-T cell therapies, and personalized genetic profiling, the landscape of neuro-oncology is rapidly changing. The development of non-invasive diagnostic tools and predictive models is also helping clinicians better assess tumor behavior and patient prognosis. This research is instrumental in improving long-term outcomes and offering hope to patients affected by malignant brain tumors.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States